

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 47/48	A2	(11) International Publication Number: WO 91/11201 (43) International Publication Date: 8 August 1991 (08.08.91)
(21) International Application Number: PCT/GB91/00104 (22) International Filing Date: 24 January 1991 (24.01.91) (30) Priority data: 9001641.1 24 January 1990 (24.01.90) GB (71) Applicant (for all designated States except US): IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED [GB/GB]; Sardinia House, Sardinia Street, London WX2A 3NL (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : EPENETOS, Agamem- non, Antoniou [GB/GB]; ROWLINSON-BUSZA, Gail [GB/GB]; Imperial Cancer Research Fund, Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London W12 0HS (GB).		(74) Agent: BASSETT, Richard, S.; Eric Potter & Clarkson, St Mary's Court, St Mary's Gate, Nottingham NG1 1LE (GB). (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (Eu- ropean patent), GB, GB (European patent), GR (Euro- pean patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: COMPOUNDS (57) Abstract A conjugate compound comprises a cell-specific portion, such as an antibody specific to tumour cell antigens, and an enzymatically active portion which will cleave a cyanogenic compound to release cyanide. Enzymes such as β -glucosidases are suitable. The cyanogenic compound, e.g. amigdaline or some other plant-derived saccharide, is administered after the conjugate. Intra-vesical (intra-bladder) administration is preferred (for bladder cancers) and forms a further aspect of the invention, whether the compound is cyanide-liberating (as above) or suitable for therapy or imaging in any other way.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

COMPOUNDS

The present invention relates to potentially cytotoxic combinations of compounds which may be targeted to selected cells.

Bagshawe and his co-workers have disclosed (Bagshawe, *Br. J. Cancer* (1987) 56, 531; Bagshawe *et al*, *Br. J. Cancer* (1988) 58, 700; WO 88/07378) conjugated compounds comprising an antibody or part thereof and an enzyme, the antibody being specific to tumour cell antigens and the enzyme acting to convert an innocuous pro-drug into a cytotoxic compound. The pro-drug is administered with, or following, the conjugate and tumour cells are thereby killed. The cytotoxic compounds were alkylating agents, eg a benzoic acid mustard released from para-N-bis(2-chloroethyl)aminobenzoyl glutamic acid by the action of *Pseudomonas* sp. CPG2 enzyme. We have now devised improved systems using different pro-drugs.

One aspect of the present invention provides a compound comprising a target cell-specific portion and an enzymatically active portion, the enzymatically active portion being capable of generating cyanide from a cyanogenic pro-drug.

The liberated cyanide is toxic to cells in the vicinity (and, because it diffuses rapidly, may kill target cells which do not exhibit whatever is recognised by the compound but which are

close to target cells which do exhibit what is recognised) but is quickly metabolised by endogenous enzymes, for example the rhodanase found in liver and kidney cells.

The entity which is recognised may be any suitable entity which is expressed by tumour cells, virally-infected cells, pathogenic microorganisms, cells introduced as part of gene therapy or even normal cells of the body which, for whatever reason, one wishes to destroy, but which entity is not expressed, or at least not with such frequency, in cells which one does not wish to destroy. The entity which is recognised will often be an antigen. Examples of antigens include those listed in Table 1 below. Monoclonal antibodies which will bind specifically to many of these antigens are already known (for example those given in the Table) but in any case, with today's techniques in relation to monoclonal antibody technology, antibodies can be prepared to most antigens. The antigen-specific portion may be an entire antibody (usually, for convenience and specificity, a monoclonal antibody), a part or parts thereof (for example an F_{ab} fragment or $F(ab')_2$) or a synthetic antibody or part thereof. A conjugate comprising only part of an antibody may be advantageous by virtue of being cleared from the blood more quickly and may be less likely to undergo non-specific binding due to the F_c part. Suitable monoclonal antibodies to selected antigens may be prepared by known techniques, for example those disclosed in "Monoclonal Antibodies: A manual of techniques", H Zola (CRC Press, 1988) and in "Monoclonal Hybridoma

Antibodies: Techniques and Applications", J G R Hurrell (CRC Press, 1982). All references mentioned in this specification are incorporated herein by reference. Bispecific antibodies may be prepared by cell fusion, by reassociation of monovalent fragments or by chemical cross-linking of whole antibodies, with one part of the resulting bispecific antibody being directed to the cell-specific antigen and the other to the enzyme. The bispecific antibody can be administered bound to the enzyme or it can be administered first, followed by the enzyme. Methods for preparing bispecific antibodies are disclosed in Corvalan et al (1987) *Cancer Immunol. Immunother.* 24, 127-132 and 133-137 and 138-143. Bispecific antibodies, chimaeric antibodies and single chain antibodies are discussed generally by Williams in *Tibtech*, February 1988, Vol. 6 36-42, Neuberger et al (8th *International Biotechnology Symposium*, 1988, Part 2, 792-799) and Tan and Morrison (*Adv. Drug Delivery Reviews* 2, (1988), 129-142).

Suitably prepared non-human antibodies can be "humanized" in known ways, for example by inserting the CDR regions of mouse antibodies into the framework of human antibodies.

IgG class antibodies are preferred.

Table 11. Tumour Associated Antigens

<u>Antigen</u>	<u>Antibody</u>	<u>Existing Uses</u>
Carcino-embryonic Antigen	{C46 (Amersham) {85A12 (Unipath)	Imaging & Therapy of colon/ rectum tumours.
Placental Alkaline Phosphatase	H17E2 (ICRF, Travers & Bodmer)	Imaging & Therapy of testicular and ovarian cancers.
Pan Carcinoma	NR-LU-10 (NeoRx Corporation)	Imaging & Therapy of various carcinomas incl. small cell lung cancer.
Polymorphic Epithelial Mucin (Human milk fat globule)	HMFG1 (Taylor- Papadimitriou, ICRF)	Imaging & Therapy of ovarian cancer, pleural effusions.
β -human Chorionic Gonadotropin	W14	Targeting of enzyme (CPG2) to human xenograft choriocarcinoma in nude mice. (Searle et al (1981) <i>Br. J. Cancer</i> 44, 137-144)

a Carbohydrate on L6 (IgG2a)¹
Human Carcinomas

Targeting of alkaline
phosphatase. (Senter et al
(1988) *P.N.A.S.* 85, 4842-
4846

CD20 Antigen on 1F5 (IgG2a)²
B Lymphoma (normal
and neoplastic)

Targeting of alkaline
phosphatase. (Senter et al
(1988) *P.N.A.S.* 85, 4842-
4846

¹Hellström et al (1986) *Cancer Res.* 46, 3917-3923

²Clarke et al (1985) *P.N.A.S.* 82, 1766-1770

Other antigens include alphafoetoprotein, Ca-125 and prostate
specific antigen.

2. Immune Cell Antigens

Pan T Lymphocyte	OKT-3 (Ortho)	As anti-rejection therapy
Surface Antigen (CD3)		for kidney transplants.

B-lymphocyte	RFB4 (Janossy,	Immunotoxin therapy of B
Surface Antigen	Royal Free	cell lymphoma.

(CD22) Hospital)

Pan T lymphocyte	H65 (Bodmer,	Immunotoxin treatment of
Surface Antigen	Knowles ICRF,	Acute Graft versus Host
(CD5)	Licensed to Xoma	disease, Rheumatoid
	Corp., USA)	Arthritis.

3. Infectious Agent-Related Antigens

Mumps virus-	Anti-mumps	Antibody conjugated to
related	polyclonal	Diphtheria toxin for
	antibody	treatment of mumps.

Hepatitis B	Anti HBs Ag	Immunotoxin against
Surface Antigen		Hepatoma.

Alternatively, the entity which is recognised may or may not be antigenic but can be recognised and selectively bound to in some other way. For example, it may be a characteristic cell surface receptor such as the receptor for melanocyte-stimulating hormone (MSH) which is expressed in high numbers in melanoma cells. The cell-specific portion may then be a compound or part thereof which specifically binds to the entity in a non-immune sense, for example as a substrate or analogue thereof for a cell-surface enzyme or as a messenger. In the case of melanoma cells, the cell-specific portion may be MSH itself or a part thereof which binds to the MSH receptor. Such MSH peptides are disclosed in, for example, Al-Obeidi *et al* (1980) *J. Med. Chem.* 32, 174. The specificity may be indirect: a first cell-specific antibody may be administered, followed by a compound of the invention directed against the first antibody. Preferably, the entity which is recognised is not secreted to any relevant extent into body fluids, since otherwise the requisite specificity may not be achieved.

The pro-drug may be any compound which is relatively non-toxic but which may be acted upon to yield cyanide. It is preferred that the non-cyanide product of the reaction is either non-toxic or, like the cyanide, is quickly metabolised to a non-toxic form on spreading from the site of action. Suitable compounds include amygdalin (D-mandelonitrile- β -D-glucosido-6- β -D-glycoside; [(6-O- β -D-glucopyranosyl- β -D-glucopyranosyl)oxy]benzene acetonitrile; "Laetrile"), or the DL

racemic mixture, and dhuririn (hydroxyamygdalin), which are disaccharides, and prunasin and linamarin, which are both monosaccharides. Further cyanogenic compounds are being discovered all the time, often in plants. Amygdalin is preferred as it has been used in cancer therapy already (although without significant success) and is relatively non-toxic, at least when administered parenterally and non-concurrently with foods such as raw almonds which are rich in β -glucosidase.

The enzymatically active portion of the compound of the invention will be chosen by reference to the pro-drug. As in the case of the naturally-occurring pro-drugs themselves, more enzymes are being found all the time. Current examples include hydroxynitrile lyases from *Prunus amygdalus*, *P. laurocerasus*, *P. serotina*, *P. lyonii*, *Sorghum bicolor*, *S. vulgare*, *Linum usitatissimum*, *Manihot esculenta*, *Hevea brasiliensis* and *Davallia trichomanoides*. At least some of these are β -glycosidases, more particularly β -glucosidases, E.C. 3.2.1.21. These enzymes and their substrates are reviewed generally in the chapter entitled "Enzymology of plant cyanogenesis" by Poulton in "Cyanide Compounds in Biology" (Ciba Symposium No.140) Ed. Evered & Harnett, Wiley 1988, which is incorporated herein by reference. It is likely that the enzymatically active portion of the compound will be enzymatically active in isolation from the cell-specific portion but it is necessary only for it to be

enzymatically active when (a) it is in combination with the cell-specific portion and (b) the compound is attached to or adjacent target cells.

The two portions of the compound of the invention are linked together by any of the conventional ways of cross-linking polypeptides, such as those generally described in O'Sullivan *et al Anal. Biochem*, (1979) **100** 100-108. For example, the antibody portion may be enriched with thiol groups and the enzyme portion reacted with a bifunctional agent capable of reacting with those thiol groups, for example the N-hydroxysuccinimide ester of iodoacetic acid (NHIA) or N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP). Amide and thioether bonds, for example achieved with m-maleimidobenzoyl-N-hydroxysuccinimide ester, are generally more stable *in vivo* than disulphide bonds.

It may not be necessary for the whole enzyme to be present in the compound of the invention but, of course, the catalytic portion must be present. So-called "abzymes" may be used, where a monoclonal antibody is raised to a compound involved in the reaction one wishes to catalyse, usually the reactive intermediate state. The resulting antibody can then function as an enzyme for the reaction.

The antibody-enzyme conjugate may be purified by size exclusion or affinity chromatography, and tested for dual biological activities. The antibody immunoreactivity is measured using an

enzyme-linked immunosorbent assay (ELISA) with immobilised antigen and in a live cell radio-immunoassay. An enzyme assay is used for β -glucosidase using a substrate which changes in absorbance when the glucose residues are hydrolysed, such as ONPG (o-nitrophenyl- β -D-glucopyranoside), liberating 2-nitrophenol which is measured spectrophotometrically at 405 nm.

Stability of the conjugate may be tested *in vitro* initially by incubating at 37°C in serum, followed by size exclusion FPLC analysis. Stability *in vivo* can be tested in the same way in mice by analysing the serum at various times after injection of the conjugate. In addition, it is possible to radiolabel the antibody with ^{125}I , and the enzyme with ^{131}I before conjugation, and to determine the biodistribution of the conjugate, free antibody and free enzyme in mice.

Alternatively, the compound may be produced as a fusion compound by recombinant DNA techniques whereby a length of DNA comprises respective regions encoding the two portions of the compound of the invention either adjacent one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the compound. Conceivably, the two portions of the compound may overlap wholly or partly. The DNA is then expressed in a suitable host in known ways.

The compounds of the invention are administered in any suitable way, usually parenterally, for example intravenously, intraperitoneally or, preferably (for bladder cancers), intravesically (ie into the bladder), in standard sterile, non-pyrogenic formulations of diluents and carriers, for example isotonic saline (when administered intravenously). Once the compound has bound to the target cells and been cleared from the bloodstream (if necessary), which typically takes a day or so, the pro-drug is administered, usually as a single infused dose. If needed, because the compound of the invention may be immunogenic, cyclosporin or some other immunosuppressant can be administered to provide a longer period for treatment but usually this will not be necessary.

The timing between administrations of antibody-enzyme conjugate and amygdalin may be optimised in a non-inventive way since tumour/normal tissue ratios of conjugate (at least following intravenous delivery) are highest after about 4 - 6 days, whereas at this time the absolute amount of antibody bound to the tumour, in terms of percent of injected dose per gram, is lower than at earlier times. Therefore, the optimum interval between administration of the conjugate and the pro-drug will be a compromise between peak tumour concentration of enzyme and the best distribution ratio between tumour and normal tissues.

The dosage will be chosen by the physician according to the usual criteria. At least in the case of methods employing intravenous amygdalin as the toxic pro-drug, 1 to 50 daily doses of 0.1 to 10.0 grams per square metre of body surface area, preferably 1.0-5.0 g/m² are likely to be appropriate. For oral therapy, three doses per day of 0.05 to 10.0g, preferably 1.0-5.0g, for one to fifty days may be appropriate. The dosage of the compound of the invention will similarly be chosen according to normal criteria, particularly with reference to the type, stage and location of the tumour and the weight of the patient. The duration of treatment will depend in part upon the rapidity and extent of any immune reaction to the antibody or enzyme component of the compound.

The compounds of the invention, together with an appropriate pro-drug, are in principle suitable for the destruction of cells in any tumour or other defined class of cells selectively exhibiting a recognisable (surface) entity, provided only that the cells (or neighbouring ones which one wishes to kill) are respiring aerobically, since cyanide is toxic by virtue of interfering with the electron transport pathway in oxidative phosphorylation. The compounds are principally intended for human use but could be used for treating other mammals, including dogs, cats, cattle, horses, pigs and sheep.

The methods of the invention may be particularly suitable for the treatment of bladder carcinoma *in situ*, administering the antibody-enzyme conjugate and the amygdalin intravesically. Our studies on the administration of radiolabelled antibodies via this route indicate that high tumour/normal bladder ratios can be achieved, and that the antibody does not enter the circulation. Bladder cancer accounts for 2% of all human malignancies, of which approximately 70% of cases are superficial at the time of diagnosis. Recurrences occur in as many as 80% of cases after surgical resection, 10% of these progressing to a higher grade carcinoma with poorer prognosis (Newling 1990). Any amygdalin which is able to enter the circulation will not be converted to cyanide, as there is no mammalian enzyme which catalyses this hydrolysis, and the conjugate will not enter the circulation from the bladder. If a small amount of free cyanide is able to enter the circulation it will be rapidly detoxified to thiocyanate and excreted.

Intravesical administration of labelled or conjugated cell-specific compounds specific for superficial bladder cancers forms a second aspect of the invention. The cell-specific compounds need not be compounds according to the first aspect of the invention: instead of having an enzymatically active portion for the liberation of cyanide, they may have an enzymatically active portion for the conversion of any other relatively non-toxic pro-drug into a toxic drug (for example the enzyme systems of Bagshawe, *loc. cit.*), or a toxic portion which

does not require conversion (eg a sufficiently active radiolabel) or a less active radio- or nmr label for imaging rather than therapy.

Thus, this second aspect of the invention provides a method of administering intravesically a compound comprising a first portion capable of binding *in vivo* to a superficial bladder cancer and a second portion capable either of being detected and localised within a living animal body to which the compound is administered or of destroying or inhibiting the growth of the said cancer cells exposed to the compound.

A "compound" in this context is any single chemical compound or association of the first and second portions which will persist under the conditions of use at least until the compound is bound to the cancer. The first and second portions may be contiguous or separated by intervening regions. There may be more than one occurrence of the first and/or second portions in any given molecule of the invention, and such repetition may be exact or inexact.

The term "capable of" means, for the first portion, capable of binding to the cancer when the first portion is part of the compound of the invention; for the second portion, it means capable of its said function as part of the compound or following binding of the compound to the cancer and cleavage or dissociation of the second portion from the compound.

The term "destroying or inhibiting growth" means in each case, to a clinically useful extent. "Growth" includes growth of the cells to which the compound binds, growth of neighbouring tumour cells and metastasis from either group of cells. The term "localised" means the derivation of information regarding the location and, often, size and shape of the tumour *in vivo*.

The first portion of the compound may be an antibody specific for a bladder tumour antigen or modified versions (eg bispecific antibodies) and fragments thereof as described above in relation to the first aspect of the invention.

The second portion, when used in a compound for diagnosis, usually comprises a radioactive atom for scintigraphic studies, for example technetium 99m (^{99m}Tc) or iodine-123 (^{123}I), or a spin label for nuclear magnetic resonance (nmr) imaging (also known as magnetic resonance imaging, mri), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

When used in a compound for selective destruction of the tumour, the second portion may comprise a highly radioactive atom, such as iodine-131, rhenium-186, rhenium-188 or yttrium-90, which emits enough energy to destroy neighbouring cells, or a cytotoxic chemical compound such as methotrexate, adriamycin, vinea alkaloids (vincristine, vinblastine, etoposide), daunorubicin and other intercalating agents or (preferably) an

enzyme or enzymatic portion thereof which converts a non-toxic pro-drug into a toxic form. In the latter case, the compound of the invention is administered and, once there is an optimum balance between (i) the tumour to normal cell ratio of compound and (ii) the absolute level of compound associated with the tumour, the pro-drug is administered either systemically (eg intravenously) or intravesically, into the bladder. The enzyme/pro-drug systems of Bagshawe and his co-workers may be used (*loc. cit.* or the antibody-alkaline phosphatase conjugates, followed by etoposide phosphate, of Senter *et al* (1988 *PNAS* 85, 4842-4846) or, more preferably, the cyanide-liberating systems described in detail above and below.

The radio- or other labels may be incorporated in the compound of the invention in known ways. For example, the first portion may be biosynthesized or may be synthesized by chemical amino acid synthesis using suitable amino acid precursors involving, for example, fluorine-19 in place of hydrogen. In such a compound, the first portion incorporates the second portion. Labels such as ^{99m}Tc , ^{123}I , ^{186}Rh , ^{188}Rh and ^{111}In can be attached via cysteine residues in the first portion or via cysteine residue. Yttrium-90 can be attached via a lysine residue. The IODOGEN method (Fraker P. J. *et al* (1978) *Biochem. Biophys. Res. Commun.* 80, 49-57) can be used to incorporate iodine-123. The book "Monoclonal Antibodies in Immunoscintigraphy" by J-F Chatal (CRC Press 1989) describes other methods in detail. When the second portion is a peptide (for example an enzyme or part

thereof), which term includes oligopeptides and polypeptides, and is contiguous with the first portion or is joined thereto by a further peptide, then the compound may be produced by expression of a suitable coding sequence in a suitable microbial or other host in known ways, either *per se* or as a fusion product for subsequent cleavage. All these methods of production and the said coding sequences form further aspects of the invention.

The invention will now be illustrated by the following examples.

EXAMPLE 1

Materials. Almond emulsion β -D-glucosidase (BDH Chemical Co, Poole, Dorset, UK). Monoclonal antibodies H17E2 (obtainable from the Imperial Cancer Research Fund, London, UK or from Unipath, Bedford, UK) and HMFG1. H17E2 is a murine monoclonal antibody of the IgG1 subclass. It was raised in BALB/c mice immunised with human term-placental plasma membranes, and recognises human placental alkaline phosphatase (PLAP) as well as the leucine-inhibitable form of the enzyme found at low levels in the healthy testis. H17E2 reacts strongly with neoplasms of the testis, ovary and cervix, and with the PLAP-secreting cell line used in the present studies.

HMFG1, also IgG1, was raised in BALB/c mice using delipidated human milk fat globule as immunogen (Taylor-Papadimitriou *et al*, 1981 *Int. J. Cancer* 28, 17-21). It is directed to a determinant on the carbohydrate side chains of a high molecular weight ($M_r > 400,000$) glycoprotein normally produced by the lactating human mammary epithelial cell, but also found on some carcinomas, such as those of breast, ovary, lung and the gastrointestinal tract.

Protein conjugation. The antibody and enzyme were conjugated using the heterobifunctional cross-linker m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (MBS) (Pierce Chemical Company, Rockford, IL, USA). The β -glucosidase was dissolved in 0.05 M phosphate buffer (pH 8) to a concentration of 5 mg/ml, and then MBS, dissolved in the same buffer, was added at a molar ratio of 20:1 (MBS:enzyme) and the mixture allowed to react at room temperature for 1 hr. The unreacted MBS was removed by G-25 gel filtration (Pharmacia, Uppsala, Sweden) using 0.05 M sodium acetate containing 1 mM ethylenediaminetetraacetate (EDTA) and 0.15 M sodium chloride (pH 6.5) as elution buffer. The derivatised enzyme was concentrated in an ultrafiltration cell (Amicon, Danvers, MA, USA) to 5 mg/ml and stored under nitrogen at 4°C.

Both the specific and control antibodies were thiolated using 2-iminothiolane hydrochloride (2IT) (Sigma) in 0.1M tri-ethanolamine buffer (pH 8.7) for 1 h at room temperature, at a

molar ratio of 50:1 (2IT:antibody). The thiolated antibody was separated from the free 2IT using a G-25 column and the same elution buffer as above. The protein-containing fractions were run directly into the derivatised enzyme, concentrated to 5 mg/ml and reacted under nitrogen at 4°C overnight. An enzyme:antibody molar ratio of 2:1 was employed in order to ensure that no unconjugated antibody remained after the reaction. It was therefore possible to separate the antibody-enzyme conjugate from free β -glucosidase on a protein A-Sepharose column (Pharmacia), using phosphate buffer (pH 8) to wash the free β -glucosidase from the column, and citrate buffer (pH 6) to remove the bound antibody-enzyme conjugate.

The purity of the conjugate before and after protein A-Sepharose was tested using fast protein liquid chromatography (FPLC) on a Superose-6 column (Pharmacia). The molecular weight of the conjugate was estimated using sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The conjugate was tested for dual biological activities using an enzyme-linked immunosorbent assay (ELISA) on plates coated with antigen (PLAP), and using the enzyme assay described below.

Cytotoxicity in vitro. The human epidermoid carcinoma cell line H.Ep-2 was originally obtained from a metastatic nodule in the neck of a male patient with a primary tumour of the larynx. It was established in tissue culture after two generations in X-irradiated, cortisone-treated rats. Immunocytochemistry has

shown the cells to bind the H17E2 antibody, but not HMFG1, which was used as a negative control in these studies. Cells were cultured in RPMI 1640 tissue culture medium supplemented with 10% foetal calf serum (Gibco Ltd, Paisley, Scotland). For cell survival experiments, after harvesting with 0.02% EDTA, 5×10^5 cells were plated in quadruplicate into 25-cm² Falcon flasks (Becton Dickinson, New Jersey, USA). Twenty-four hours later the cytotoxic agent was added (either amygdalin alone, β -glucosidase alone, amygdalin plus β -glucosidase, potassium cyanide alone, amygdalin plus H17E2- β -glucosidase conjugate or amygdalin plus HMFG1- β -glucosidase conjugate). After 24 h exposure, the medium containing the drug was replaced with fresh medium and the cells allowed to grow for a further 24 h before counting by haemocytometry, using trypan blue exclusion as the criterion for cell integrity.

Flow cytometry. After incubation with the specific conjugate, H.Ep-2 cells were tested for the presence of H17E2 antibody and β -glucosidase using flow cytometry. The cells were washed twice in tissue culture medium and resuspended at a concentration of 5×10^6 cells/ml. The presence of H17E2 on the surface of cells was tested by incubating 100 μ l of cell suspension with F(ab')₂ fragments of a rabbit anti-mouse-IgG antibody conjugated to fluorescein isothiocyanate (FITC) (Dako, High Wycombe, Bucks) for 30 min on ice. The presence of the enzyme was tested by incubating an aliquot of the cell suspension with a polyclonal rabbit anti- β -glucosidase antibody produced in our laboratory.

After 1 h incubation, the cells were incubated with FITC-conjugated swine anti-rabbit-IgG antibody (Dako) for 30 min on ice. The FITC on the cell surface was measured using an EPICS V flow cytometer.

Enzyme assay. The β -glucosidase activity was assayed in 0.05 M acetate buffer (pH 6) using 2-nitrophenyl- β -D-glucopyranoside (BDH Chemical Co) as the chromogenic substrate. The assay was performed in 96-well plates and the reaction stopped after 10 min by the addition of 0.2 M sodium carbonate (pH 12). The absorbance of the product (2-nitrophenol) was measured at 405 nm in a Titertek Multiskan MCC/340 plate reader (Flow Laboratories, Helsinki, Finland).

Results

The cytotoxicity *in vitro* of the H.Ep-2 cell line to amygdalin alone, amygdalin in the presence of 0.35 μ M or 3.5 μ M β -glucosidase, and potassium cyanide alone was measured. The IC_{50} (dose required to give 50% cell survival) for each of these agents was found to be 114 ± 8 , 0.6 ± 0.3 , 0.5 ± 0.2 and 0.2 ± 0.1 mM, respectively. This indicates that although amygdalin is non-toxic to the cells except at very high concentrations, it is readily converted to the toxic compound by β -glucosidase at physiological pH and temperature, and is then able to kill cells almost as effectively as cyanide itself.

Analysis of the conjugate using FPLC showed a single peak which eluted earlier than the free antibody or enzyme. SDS-PAGE analysis of the same sample indicated that this peak corresponded to a molecular weight slightly higher than 200,000, consistent with the expected value for the β -glucosidase-antibody conjugate.

An assay of the immunoreactivity of the H17E2 antibody and the conjugate showed only slight loss of ability to bind PLAP after conjugation to β -glucosidase.

Table 1 shows the results of an enzyme assay of the H17E2- β -glucosidase conjugate at 100 nM, and the native enzyme at three concentrations. The mean K_m of the β -glucosidase at the three concentrations was determined to be 9.4 mM, and that of the conjugate to be 10.6 mM. Since the V_{max} for the conjugate and enzyme at the same concentration was unchanged, the increase in K_m indicates a loss of enzyme activity of 13%.

Table 1

Enzyme assay of β -glucosidase and H17E2- β -glucosidase conjugate using 2-NPG as substrate. Values of K_m and A_{max} were obtained from Lineweaver-Burk plots.

<u>Sample</u>	<u>Concentration (nM)</u>	<u>K_m (mM)</u>	<u>A_{max}</u>
β-glucosidase	20	9.4	0.5
β-glucosidase	50	9.3	1.3
β-glucosidase	100	9.5	2.5
H17E2-conjugate	100	10.6	2.5

Flow cytometry of cells incubated with H17E2-β-glucosidase conjugate showed that both antibody and enzyme were present on the cell surface, 99% of cells being positive for both proteins. Similar results were achieved with immunocytochemistry.

In terms of the cytotoxic effect on H.Ep-2 cells of β-glucosidase alone or in the presence of 1 mM amygdalin, the enzyme alone is non-toxic up to much higher concentrations than are necessary to activate amygdalin (ie 0.35 μM). As a comparison at one enzyme concentration (50 nM) of the antibody-enzyme conjugate or an unconjugated mixture of H17E2 and β-glucosidase in the presence of 1 mM amygdalin, it was found that the treated/control cell survival ratio is 0.68 ± 0.15 for the unconjugated mixture compared with 0.39 ± 0.09 for the conjugate (mean \pm standard deviation, $p < 0.05$). In order to achieve cell killing at this level with unconjugated β-glucosidase, a 10-fold increase in enzyme concentration is necessary. The effect on H.Ep-2 cells of varying concentrations of amygdalin activated by 50 nM β-glucosidase alone, 50 nM specific H17E2-β-glucosidase conjugate or 50 nM control HMFG1-β-glucosidase conjugate was

measured. The HMFG1-conjugate displayed no significant advantage over unconjugated β -glucosidase at any of the amygdalin concentrations (0.1, 1.0, 10.0 mM). The cytotoxicity of the specific conjugate at both amygdalin concentrations (1.0, 10.0 mM) is significantly greater than that of the control conjugate or the unconjugated enzyme plus amygdalin at the same concentration ($p < 0.05$). This corresponds to approximately a 5-fold reduction in the concentration of amygdalin required to produce the same cytotoxicity.

Summary

Amygdalin was more cytotoxic in the presence of the specific antibody-enzyme conjugate than the control conjugate or an unconjugated mixture of antibody and enzyme plus amygdalin at the same concentration, due to the cell-bound enzyme releasing a high concentration of cyanide in the tumour cell vicinity. This overcomes the problems of antigen heterogeneity and the necessity for internalisation of the cytotoxic compound, which limit the cytotoxicity of antibody-drug immunoconjugates. For example, a methotrexate-antibody complex has previously been found to be less potent than the free drug for human colon carcinoma cells *in vitro*, even with 5 molecules of methotrexate per conjugate.

Since the pro-drug is relatively non-toxic, and the enzyme is localised to the tumour site, with no endogenous homologue activity, multiple injections of prodrug may be administered while the antibody-enzyme conjugate remains bound to tumour cells, thereby increasing the differential (drug concentration x time) between tumour and normal tissues. Any free cyanide which diffuses away from the tumour site will be detoxified to thiocyanate by rhodanase, a widely distributed mammalian enzyme found in high concentrations in liver and kidney.

EXAMPLE 2

Patients and methods. 23 patients undergoing cystoscopy for known or suspected bladder carcinoma entered the study. Each patient gave written consent before entering the study. Four patients were studied twice and one three times: a total of 29 instillations were performed.

150-200 µg of AUA1 or 11.4.1. monoclonal antibody, labelled with 0.3-0.5 mCi of ¹¹¹In and diluted in 50 ml of 0.9 g per 100 ml NaCl solution were administered intravesically through a catheter. AUA1 was administered in 22 and 11.4.1. in 7 cases. The radiolabelled antibody was kept in the bladder for 1 h during which patients were encouraged to change position every 15 min. The bladder was then emptied and washed twice with 50 ml of 0.9 g per 100 ml NaCl solution. AUA1 monoclonal antibody is an IgG1 mouse immunoglobulin recognising a 35 kDa

glycoprotein present on the membrane of various types of epithelial cells. It reacts with a restricted number of normal epithelial tissues and most human carcinomas where it is expressed more intensely than in normal tissues (Spurr, N. K. et al (1986) *Br. J. Cancer.* 38, 631-636). 11.4.1. monoclonal antibody is an IgG1 mouse immunoglobulin which recognises an HLA component of mouse lymphocytes and does not react with any human tissues. It was used as a negative control (Oi, V. T. et al (1979) *Curr. Topic. Microbiolo. Immunol.* 81, 115-110).

The monoclonal antibodies were coupled with DTPA (Sigma, UK) using the method of Hnatowich et al ((1983) *J. Immunol. Meth.* 65, 147-152). Briefly, DTPA was added to the antibodies (10 mg/ml) at a molar ratio 10:1. The reaction was carried out at room temperature and pH 8.0 for 10 min. Free DTPA was removed using a Sephadex G50 column. Protein containing fractions were collected, Millipore filtered and stored at -70°C. ¹¹¹In (Amersham, UK) was added to DTPA coupled antibodies and reacted for 30 min at room temperature at pH 6.5. Free ¹¹¹In was removed using a Sephadex G50 column. 60%-70% of ¹¹¹In was bound to AUA1 and 85%-90% to control antibody. The specific activity ranged from 2-3 mCi/mg. Immunoreactivity of AUA1 before and after administration into the bladder was tested using an ELISA and competition RIA. *In vivo* stability of both antibodies was tested by SDS-PAGE and gel autoradiography. Cystoscopy was performed at 2 h (n=14), 24 h (n=12) and 48 h (n=3) after instillation. Samples from tumours as well as from normal areas

were taken during cystoscopy. They were fresh frozen or fixed in Methacarn. Samples were weighed and then counted in a gamma-counter for radioactivity. They were then processed and embedded in paraffin. Blood samples were obtained at 2h, 1, 2, and 3 days after the instillation and counted for radioactivity. Haematoxylin-Eosin and a two step immunoperoxidase method using AUA1 and control antibody were performed on paraffin and frozen sections. Data were analysed statistically using the Student's t-test.

ELISA and RIA showed that instillation into the urinary bladder caused no loss of AUA1 immunoreactivity. Autoradiography of the gel after instillation showed that practically all ^{111}In was bound to the antibodies.

Tumour was found in 20 out of 29 cases studied (Tis:1, Ta:17, T1:1, T2:1; Grade I:9, Grade II:6, Grade III:4). Eighteen of the tumours were papillary, one anaplastic and one was *in situ* carcinoma. The samples taken from normal areas consisted of normal urothelium with chronic inflammatory infiltration in a few of these cases. In one case (instillation performed 2h before the cystoscopy) no normal samples were taken. Immunohistochemical analysis showed a weak reaction of AUA1 with the basal layer of the normal urothelium while all the tumours showed a more intense reaction. The intensity of the staining and the number of the positive cells increased with the grading of the tumours. Grade I tumours reacted only on the lower third

of the epithelium at a depth of 1-2 cells while Grade II tumours reacted more strongly on the lower and the middle third of the epithelium. Grade III tumours showed intense reaction of 70%-100% of the cells. *In situ* carcinoma was also positive. Immunostaining using 11.4.1. was negative in all cases.

Radioactivity targeted on the tumours and normal tissues, at various time points after AUA1 administration, showed that the uptake by the tumours, in all cases, was higher than that of normal tissues of the same patients. The mean uptake of both antibodies on tumour and non-tumour samples is shown in Table 1.

Table 1: Mean uptake of tumour^a and non-tumour tissues.

150-200 µg of AUA1 or 11.4.1. labelled with 0.3-0.5 mCi of ¹¹¹In were administered intravesically and remained in the bladder for 1h. Cystoscopy was performed at 2h, 24h and 48h after the instillation. Tumour and non-tumour samples were taken and counted for radioactivity. The presence of tumour in the samples was determined after histological examination.

29

Time after

instillation

2

24

48

(h)

Antibody

AUA1

Tumour	6.12 \pm 5.50 (n=6)	1.70 \pm 2.57 (n=7)	0.30 \pm 0.17 (n=3)
Non-tumour	0.32 \pm 0.50 (n=10)	0.22 \pm 0.30 (n=8)	0 (n=3)

Antibody

11.4.1.

Tumour	0.075 \pm 0.075 (n=2)	0.025 \pm 0.025 (n=2)	-
Non-tumour	0.30 \pm 0.42 (n=3)	0.15 \pm 0.26 (n=4)	-

^aexpressed as 10^3 x percentage of injected dose/g of tissue

It must be emphasised that in 5 out of 9 cases at 2 h, 4 out of 8 at 24 h and in all 3 cases at 48 h there was no uptake in the non-tumour samples. When 11.4.1. was administered no activity was found in tumour samples in 2 out of 4 cases while in the remaining 2 cases the uptake was more than 30-fold lower than the respective values for specific antibody. There was no radioactivity in the blood of the patients at any of the time points they were counted. Statistical analysis of the results show that there is significant difference between the uptake of AUA1 in tumour and non-tumour samples at 2 h and 48 h ($p < 0.05$) after the instillation and between the tumour uptake of AUA1 and 11.4.1. at 2 h ($p < 0.05$). The correlation between tumour uptake of AUA1 and the grade of the tumours is shown in Table 2. The

uptake increased with the grade of the tumours. There is a significant difference between the uptake by the normal tissue and the Grade II tumours at both 2 h ($p < 0.05$) and 24 h ($p < 0.001$) after the instillation.

Table 2: Correlation of the grade of the tumours with the mean uptake^a of AUA1.

Time after instillation (h)	2	24	48
Grade			
I	0.2 (n=1)	0.36 \pm 0.49 (n=4)	0.40 \pm 0.13 (n=2)
II	4.9 \pm 2.8 (n=4)	1.55 \pm 0.25 (n=2)	-
III	17 (n=1)	7.35 (n=1)	-
<i>In situ</i>			0.10 (n=1)

^aexpressed as $10^3 \times$ percentage of injected dose/g of tissue.

This difference in tumour and normal uptake is favourable for immunotherapy and in fact represents one of the best achieved by using monoclonal antibodies up to date. The correlation of the uptake of the specific antibody with the grade of the tumours represents an advantage of this approach since the frequency of recurrence and invasion increases with the grade of the tumours. Grade II and especially Grade III tumours need additional treatment apart from the surgical excision. Grade I tumour

uptake showed no difference from the uptake of the normal tissues. This is probably due to the restriction of the antigenic expression of AUA1 in the basal layer of the epithelium which is difficult for the antibody to reach. Other antibodies recognising epitopes on more accessible tumour cells would probably be more suitable for these tumours.

Human anti-mouse antibody responses and myelosuppression due to the accumulation of immunoconjugates by the reticuloendothelial system represent the most serious drawbacks when monoclonal antibodies are used for cancer therapy. Intravesical administration of radiolabelled AUA1 antibody shows that there is no circulating antibody in the blood because there is no or very limited absorption from the normal urothelium. Large molecules are most unlikely to be absorbed even when employed in high doses in contrast to chemotherapeutic drugs which can diffuse into the systemic circulation and produce myelosuppression. Using our approach systemic toxicity may be avoided and repeated administrations may be given. The advantages of selective uptake of the specific antibody and its non-toxic potential also make this method ideal for the two step approach (targeted conversion of non-toxic prodrug to toxic drug) described above. These exploit the selective uptake of the antibody to deliver an enzyme or streptavidin (as an antibody-enzyme or antibody-biotin immunoconjugate) to tumour cells. After the clearance of the conjugate from the circulation and normal organs an inactive prodrug or radioactive

streptavidin is administered. The cleavage of the prodrug by the enzyme results in the generation of a toxic agent. When the streptavidin-biotin system is used, the high affinity of these substances for each other is exploited in order to deliver the radioisotope to the tumour. In the method of this Example, the interval between the two steps can be very short because there is no circulating antibody and very low or no uptake by the normal urothelium.

CLAIMS

1. A compound comprising a target cell specific portion and an enzymatically active portion, characterised in that the enzymatically active portion is capable of generating cyanide from a cyanogenic pro-drug.

2. A compound according to Claim 1 wherein the enzymatically active portion comprises at least the catalytic portion of a hydroxynitrile lyase.

3. A compound according to Claim 1 wherein the enzymatically active portion comprises at least the catalytic portion of a β -glucosidase.

4. A compound according to any one of the preceding claims wherein the target cell specific portion comprises an antibody or part thereof.

5. A compound according to any one of the preceding claims wherein the cell specific portion recognises and selectively binds to a tumour cell antigen.

6. A bispecific antibody capable of binding to a target cell specific antigen and to an enzymatically active molecule, characterised in that the said molecule is capable of generating cyanide from a cyanogenic pro-drug.

7. A therapeutic system comprising a compound according to any one of Claims 1 to 5 and a cyanogenic pro-drug which can be cleaved by the said enzymatic portion to yield cyanide.

8. A therapeutic system according to Claim 7 wherein the cyanogenic pro-drug is a mono- or di-saccharide.

9. A therapeutic system according to Claim 8 wherein the cyanogenic pro-drug is amygdalin.

10. A pharmaceutical composition for parenteral delivery comprising a compound according to any one of Claims 1 to 5.

11. A method of treating a mammal having target cells to be destroyed, the method comprising (1) administering a compound according to any one of Claims 1 to 5 to the mammal, (2) allowing the ratio of (compound bound to the target cells): (compound not bound to the target cells) to reach a desired value, and (3) administering a cyanogenic pro-drug which can be cleaved by the said enzymatically active portion to yield cyanide.

12. A method according to Claim 11 wherein the said compound and the cyanogenic pro-drug are administered directly into the bladder of the mammal.

13. A method of preparing a mammal for tumour therapy comprising administering a compound according to any one of Claims 1 to 5 or an antibody according to Claim 6 to the mammal.

14. A method of treating a mammal harbouring a tumour, the mammal having been prepared for treatment by a method according to Claim 13 wherein the said compound is administered, the method comprising administering to the mammal a cyanogenic pro-drug from which cyanide can be generated by the enzymatically active portion of the said compound.

15. A method of administering a compound to a patient to combat cancer, characterised in that the compound comprises a first portion capable of binding *in vivo* to a superficial bladder cancer and a second portion capable either of being detected and localised within the patient or of destroying or inhibiting the growth of the said cancer cells exposed to the compound, and in that the compound is administered intravesically.

16. A method according to Claim 15 wherein the second portion comprises an enzymatically active component capable of converting a relatively non-toxic pro-drug to a more toxic drug and wherein the said pro-drug is administered to the patient following administration of the said compound.

17. Any novel feature or combination of features disclosed herein.